


**Figure 1. The method used to obtain reproducible data for microarray analysis conducted on serum-extracted samples.** A. NL patients' serum were sampled twice. In the first, RNA was extracted first from untreated serum, and then extracted again from serum treated with exoquick. In the second serum sample, RNA was also extracted from both untreated serum and serum treated with exoquick. Microarray analysis was conducted for RNA in a total of four samples. B. Reproducibility test of microarray data. Scatter plots comparing non-normalized signal intensities of miRNAs in two independent experiments from human total serum and exosome rich fraction. Red and black denotes high and low miRNA expressions respectively. Total serum extracted first, versus exosome rich fraction first (left), total serum extracted first versus second (middle), and exosome rich fraction extracted first versus second (right). C. Pearson's pairwise correlations of signal intensities of miRNAs from human total serum and exosome rich fraction. D. Western blot was performed for untreated serum, serum extracted by exoquick and exosome fraction from PNT-2, using anti-CD63.  
doi:10.1371/journal.pone.0048366.g001

A




B

		result	
		CHC	NL
prediction	CHC	64	3
	NL	0	21

accuracy 96.6%

C



**Figure 2. Expression patterns of miRNA used for discriminating between CHC and NL.** A. Box plots of expression patterns of the nine miRNAs used for discriminating between CHC and NL. B. Classification of CHC and NL using LOOCV from miRNA expression profile. C. PCA in CHC and NL. The two dimensional embedding of CHC and NL by PCA. The first and second principal component scores computed (not selected for discrimination) of normalized miRNA expression were employed for this plot. Computation was done with ALL. doi:10.1371/journal.pone.0048366.g002

sively downregulated as liver fibrotic stage increased (**Fig. 6, S11** and Table S2).

### Classification of Liver Inflammation Grade and Fibrotic Stage Using miRNA Expression Pattern

We attempted to classify liver inflammation grade and fibrosis stage using miRNA expression pattern. Liver inflammation was diagnosed by Leave One Out Cross-Validation (LOOCV); the accuracy of determining A1 from other inflammation grade was 71.88% and its odds ratio was 7.08. The accuracy of determining A2 and A3 was 75.00% and 82.81%, and their odds ratios were 9.50 and 11.08, respectively. In our study, we were unable to accurately classify A0 because we were limited to only one sample for that grade (**Fig. 7A**). Diagnosis of liver fibrosis by LOOCV showed that determining F0 from the other fibrotic stages had an accuracy of 87.50% and an odds ratio of 14.25. The classification of F1, F2, and F3 had accuracy rates of 65.63%, 70.31%, and 73.44% and odds ratio of 3.16, 6.39 and 5.80, respectively (**Fig. 7B**).

### miRNA Expression Level Detected by Real-time qPCR Validated the Microarray Result

Four miRNAs (miR-1207-5p, miR-134, miR-1249, and miR-1183) with expression levels that differed among liver inflammation grades and liver fibrotic stages were chosen in order to confirm the microarray results using stem-loop based real-time qPCR. miRNAs that correlated with other clinical characteristics besides liver fibrosis and inflammation were listed using the Wilcoxon test. We performed two Wilcoxon tests and ranked miRNAs based on their p-value from smallest to largest and selected the miRNAs with the four smallest p-values that were common among the two Wilcoxon tests.

The real-time qPCR result was consistent with the microarray analysis (**Fig. 8**). Here also, we applied “*in silico*” resampling to compensate for the small number of patients used in the real-time qPCR analysis. The results of the “*in silico*” resampling conferred with the results of the real-time qPCR (**Fig. S12**).

### miRNA Expression Pattern was Closely Related to Several Clinical Parameters in CHC

Although we observed that miRNA expression correlated with ALT value, we were unable to identify miRNAs that displayed a strong correlation. 12 miRNAs were chosen sequentially from miRNAs with a high absolute correlation coefficient. One to 12 of these selected miRNAs were used to compare the canonical correlation coefficient of the above. When the expression patterns of six of the 12 miRNAs were compared with serum ALT value, the correlation coefficient and p-value were 0.44 and  $4.91E-02$ , respectively. Similarly, when serum Albumin value was compared with the expression pattern of all 12 miRNAs, the correlation coefficient and p-value were 0.59 and  $2.04E-02$ , respectively. Finally when the amount of serum HCV RNA was compared with the expression pattern of 12 miRNAs, the resulting correlation coefficient and p-value were 0.59 and  $1.89E-02$ , respectively (**Fig. 9, S13** and Table S3).

### Expression Pattern of a Several miRNAs Correlated to Serum and Hepatic Tissue

In a previous report, we described the miRNA expression pattern found in liver tissues obtained from 105 CHC [2]. From this group, we analyzed the miRNA expression of hepatic tissue and serum in 60 samples. We observed that the expression pattern of three miRNAs (miR-134, miR-200b, miR-324-5p) in hepatic tissue negatively correlated with that in serum, and the expression pattern of miR-370 in hepatic tissue positively correlated with that in serum ( $p < 0.05$ ) (Table S4). However, there was no significant correlation between the expression pattern of miR-122 in the hepatic tissue and serum (**Fig. S14** and Table S4).


### Discussion

In this comprehensive miRNA analysis in various chronic liver diseases, we observed that aberrant expression of miRNAs was closely related to disease progression. Based on this, we believe that these miRNAs are potential readily accessible biomarkers, useful for diagnosing hepatic viral infection and for grading or staging liver diseases.


Many investigators have elected to use miRNA from serum instead of miRNA from exosome as the candidate for diagnosing diseases [18,20,22,25,26]. In our study, when exoquick was used, exosome could not be isolated therefore other MVs similar in size to exosome were also extracted. In other words, exoquick not only collected miRNAs contained in exosome, but also miRNA that were or were not combined with protein. Despite this, we found that exoquick delivered results that were superior to those obtained without exoquick. Therefore, although the process of analyzing miRNA from serum is simple, we chose to analyze miRNA from exosome rich fraction since it has a higher rate of reproducibility. Moreover, since exosome is closely related to intercellular signaling [14,27], it is expected that data obtained by exosome analysis can clarify the mechanism of chronic infection and inflammation [28].

When we extended our analysis from miR-122 to all miRNAs, it became clear that the expression level of several miRNAs correlated with the progression of liver fibrosis. In fact, recent studies have stated that when the expression levels of adequate numbers of miRNAs is used to identify disease, diagnostic ability is significantly higher than using a single miRNA [29]. In this study, when liver fibrosis was diagnosed using miRNA expression, distinguishing between F0 and F1-3 was done with 87.50% accuracy. Since F0 cannot be distinguished from other stages of chronic liver disease using blood examination, we propose that using miRNA expression pattern may be useful for diagnosing chronic liver disease that is in the early stage.

Previous studies have shown that the level of miR-122 in blood plasma increased earlier than in ALT in the presence of toxic liver injury in rodents [30]. Serum levels of miR-122 in patients with CHC are frequently elevated compared with healthy individuals [21]. Bihrer et al. mentioned that variations in the concentration of miR-122 in serum or plasma tend to be more specific for liver diseases than ALT and AST. This is because miR-122 is almost exclusively expressed in the liver, whereas ALT and AST originate from skeletal muscles and other tissues, therefore their diagnostic value is low [31]. In our study, the expression level of miR-122 had



**Figure 3. Pairwise heatmap of the miRNAs used for classifying two arbitrary groups.** Pairwise heatmap showed the miRNAs and their p-value of two arbitrary groups.  
doi:10.1371/journal.pone.0048366.g003



**Figure 4. Pairwise heatmap of the miRNAs used for classifying among four groups.**  
doi:10.1371/journal.pone.0048366.g004

a significant positive correlation with the grade of liver inflammation, serum albumin value, or serum HCVRNA value. However, miR-122 expression did not significantly correlate with liver fibrosis stage. Moreover, there was no correlation between the expression level of miR-122 in liver tissue, and that in serum in the same 60 samples (Fig. S14). The expression pattern of only four miRNAs out of total liver tissue miRNAs correlated with the expression patterns of miRNA found in the serum (Table S4). Most serum miRNA had expression patterns that differed from those observed in hepatic tissue samples. Moreover, we observed differences in miRNAs expression between various tissues [32]. These differences were observed even in tissues taken from the same subject; at present we are unclear as to the reason for this phenomenon.

In regards to the progression of liver fibrosis and the expression pattern of miR-21, previous studies concur with our result that miR-21 expression level significantly decreased in response to the progression of liver fibrosis [20]. Taken together, this suggests that any miRNAs that may have been emitted from liver tissue cannot be detected in serum after hepatic cell injury.

The expression pattern of many miRNAs in serum positively correlated with serum ALT, albumin, and HCVRNA levels in this

study (Fig. 9, S13 and Table S3). This result contradicts prior assumptions that no correlation exists between serum miR-122 and HCVRNA serum levels [21]. Three likely reasons for this difference in results are: 1) the detection method used (real-time qPCR versus microarray), 2) the difference in the subjects' ages (the subjects in this study were older), and 3) the difference in the amount of miRNAs (multiple miRNAs vs. a single miRNA) used to identify the clinical parameters of the disease.

CHC and NL were classified with a high level of accuracy using the expression pattern of miRNA. In order to elucidate if the miRNA expression in CHC is common to other chronic liver diseases including CHB, we compared the miRNA expression pattern of CHC with those of NASH and CHB. The result of this analysis was that CHC could be clearly distinguished from both CHB and NASH. These results demonstrate that the varying forms of chronic liver disease have their own unique miRNA expression pattern. NASH is a histological diagnosis that rests on a combination of features and can only be confirmed by liver biopsy. Recently, NASH was diagnosed by first determining the existence of NAFLD from blood samples and then performing an ultrasound tomography. Finally, liver fibrosis stage was determined by Fibroscan

**Table 1.** Characteristics of subjects in this study of original samples and independent samples.

Original samples				
Characteristics	CHC	CHB	NASH	NL
Gender	F: 34/M: 30	F: 2/M: 2	F: 3/M: 9	F:11/M: 13
Age (years)	59.5±8.3	46.8±14.5	52.3±13.1	50.8±12.0
AST (IU/L)	50.1±29.8	83.3±53.7	46.2±16.0	N.D
ALT (IU/L)	57.6±40.6	167.8±170.3	74.5±34.9	N.D
WBC (x10 <sup>3</sup> /mm <sup>3</sup> )	5.1±1.5	4.7±1.5	6.2±1.6	N.D
Platelet (x10 <sup>9</sup> /mm <sup>3</sup> )	16.6±5.9	14.8±6.3	24.7±8.0	N.D
Total Bilirubin (mg/dl)	0.65±0.22	0.83±0.40	0.76±0.25	N.D
Weight (kg)	57.9±9.18	58.8±4.3	74.9±24.8	59.6±9.6
ALP (IU/L)	267.0±88.4	223.3±25.0	232.7±36.2	N.D
γGTP (IU/L)	46.9±42.3	77.3±82.2	58.4±20.9	N.D
Hemoglobin (g/dl)	13.8±1.2	14.5±0.59	14.7±1.6	N.D
Albumin (g/dl)	4.1±0.4	4.2±0.5	4.4±0.3	N.D
Independent samples				
Characteristics	CHC	CHB	NASH	
Gender	F: 18/M: 13	F: 10/M: 6	F: 6/M: 2	
Age (years)	59.5±8.3	46.8±14.5	54.8±12.7	
AST (IU/L)	50.1±29.8	83.3±53.7	80.9±50.0	
ALT (IU/L)	57.6±40.6	167.8±170.3	108.9±76.2	
WBC (x10 <sup>3</sup> /mm <sup>3</sup> )	5.1±1.5	4.7±1.5	5.5±1.8	
Platelet (x10 <sup>9</sup> /mm <sup>3</sup> )	16.6±5.9	14.8±6.3	19.3±7.6	
Total Bilirubin (mg/dl)	0.65±0.22	0.83±0.40	0.73±0.25	
Weight (kg)	57.9±9.18	58.8±4.3	66.4±9.9	
ALP (IU/L)	267.0±88.4	223.3±25.0	278.6±100.6	
γGTP (IU/L)	46.9±42.3	77.3±82.2	130.1±81.23	
Hemoglobin (g/dl)	13.8±1.2	14.5±0.59	13.6±1.4	
Albumin (g/dl)	4.1±0.4	4.2±0.5	3.8±0.3	

Abbreviations; CHC, chronic hepatitis C; CHB, chronic hepatitis B; NASH, non alcoholic steatohepatitis; NL, normal liver (healthy control); N.D, no data.  
doi:10.1371/journal.pone.0048366.t001

(reviewed in [33]). However, when the results of these and other measures fail to yield a diagnosis then a pathology evaluation is necessary. Using “*in silico*” resampling to increase the reliability of our data, has led us to believe that NASH diagnosis may be possibly through blood examination.

We tested the reliability of our analysis in two ways and obtained reproducible results in both cases. First we enrolled an independent sample group, and second, we created virtual cohorts using *in silico* resampling to overcome our small sample size.

In this study we concluded that miRNA profiling is a promising alternative to diagnosing liver disease. This is based on our demonstration that the following evaluations could be performed using suitable miRNA expression profiles (1) determining the stage or grade of chronic liver disease, (2) ascertaining the clinical status of chronic liver diseases, and (3) distinguishing among various forms of chronic liver diseases. While these results suggest there is great potential and benefit of

miRNA profiling, future studies in a larger population of CHC patients are warranted to fully elucidate the diagnostic potential of serum miRNA expression.

## Materials and Methods

### Patient Selection

A cohort of 64 CHC, 4 CHB, and 12 NASH patients who had undergone liver biopsy, as well as 24 healthy control subjects was enrolled. We also prepared independent samples consisting of 31 CHC, 12 CHB, and 8 NASH to validate our results. Patient characteristics are summarized in Table 1 and detailed clinical data is depicted in Table S5. The criteria for exclusion for CHC, CHB, and NASH were: co-infection with human immunodeficiency virus (HIV) types 1 and 2, decompensated liver disease, organ transplantation, immune suppression, autoimmune disorders, consumption of >20 g/day alcohol, and past history of intravenous drug abuse. Healthy controls were selected if they were not infected with HBV, HCV, nor HIV, had normal liver function tests, and had no history of liver disease.

All patients or their guardians provided written informed consent, and Ogaki Municipal Hospital and Kyoto University Graduate School and Faculty of Medicine’s Ethics Committee approved all aspects of this study in accordance with the Helsinki Declaration.

### Liver Histology and Blood Examination

A liver biopsy specimen was collected from each patient before anti-viral treatment. Histological grading and staging of CHC liver biopsy specimens were performed according to the Metavir classification system [34]. NASH was diagnosed histologically [35].

Serum HCV RNA was quantified before IFN treatment using Amplicor-HCV Monitor Assay (Roche Molecular Diagnostics Co., Tokyo, Japan), while serum HBV DNA was quantified before treatment using Amplicor HBV Monitor Assay (Roche). Pretreatment blood tests were conducted to determine each patient’s level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, gamma-glutamyl transpeptidase, white blood cell (WBC), platelets, and hemoglobin.

### Blood Sampling


Peripheral blood was collected from all subjects directly into serum tubes before anti-viral treatment. The tubes were centrifuged at 1,500 g for 10 min at 4°C, sera were aliquoted and additionally centrifuged at 2,000 g to completely remove any remaining cells. Sera were stored at –80°C until use.

### RNA Preparation

Total RNA from 200 ul of serum was prepared using miRNeasy mini kit (Qiagen, Hilden Germany) according to the manufacturer’s instruction. Exosome rich fractionated RNA was prepared using Exoquick (System Biosciences, CA, USA). Briefly, 900 ul of serum was mixed with 250 ul of Exoquick and incubated for 12 hr at 4°C. The tubes were centrifuged at 1500 g for 30 min at room temperature and then supernatant was discarded. The pellet was dissolved with 200 ul of PBS with vigorous vortex. RNA was extracted using miRNeasy mini kit (Qiagen).

### Immunoblot Analysis and Exosome Preparation

The procedure for exosome preparation has been previously described [8]. SDS-PAGE gels, SuperSep Ace 5–20% (194–15021) (Wako, Osaka, Japan), were calibrated with Precision Plus Protein Standards (161–0375) (Bio-Rad), and anti-CD63 (1:200)




**Figure 5. Significantly differentially expressed miRNAs according to liver inflammation grade.** Pairwise heatmap showing the miRNAs and p-value of two arbitrary grades.  
doi:10.1371/journal.pone.0048366.g005

was used as primary antibodies. The dilution ratio of each antibody is indicated in parentheses. Two secondary antibodies (peroxidase-labeled anti-mouse and anti-rabbit antibodies) were used at a dilution of 1:5000. Bound antibodies were visualized by chemiluminescence using the ImmunoStar LD (Wako) and luminescent images were analyzed by a LuminoImager (LAS-3000; Fuji Film, Inc.). Only gels for CD63 (BD, NJ, USA) detection were run under non-reducing conditions. To exclude the

albumin and IgG in serum, Albumin & IgG Depletion SpinTrap kit was used (GE health care, WI, USA). After aliquots isolation, exosome-contained fraction was isolated by Exoquick according to standard instructions.

#### miRNA Microarray

To detect serum miRNA, 60 ng of RNA was labeled and hybridized using the Human microRNA Microarray Kit (Rel



**Figure 6. Significantly differentially expressed miRNA according to liver fibrotic stage.** Pairwise heatmap showing the miRNAs and p-value of two arbitrary stages.  
doi:10.1371/journal.pone.0048366.g006


14.0) (Agilent Technologies, CA, USA) according to the manufacturer's protocol (protocol for use with Agilent microRNA microarrays Version 1.0). Hybridization signals were detected with a DNA microarray scanner G2505B (Agilent Technologies) and the scanned images were analyzed using Agilent feature extraction software (v9.5.3.1). We used raw data (gProcessedSignal) and normalized each expression so as to have zero mean and unit sample variance. The data presented in this manuscript have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series access number GSE33857: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33857>.

#### Real-time qPCR for Human miRNA

To detect miRNA expression level by real-time qPCR, TaqMan<sup>®</sup> microRNA assay (Applied Biosystems) was used to quantify the relative expression levels of miR-1207-5p (assay ID. 241060), miR-134 (assay ID. 000459), miR-1183 (assay ID. 002841), and miR-1249 (assay ID. 002868). The expression level of miR-16 (assay ID. 000391) was also measured and used as an internal control. cDNA was synthesized using the Taqman miRNA RT Kit (Applied Biosystems). RNA (2 ng/ml) in 5 ml of nuclease free water was added to 3 ml of 5 × RT primer, 10 × 1.5 μl of reverse transcriptase buffer, 0.15 μl of 100 mM dNTP, 0.19 μl of RNase inhibitor, 4.16 μl of nuclease free water, and 50 U of reverse transcriptase in a total volume of 15 μl. The reaction was performed for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C.




A




A1 vs A0+A2+A3	
accuracy	71.88%
Fisher's exact test	p-value: 4.07E-04
odds ratio	7.08

		result	
		F	T
prediction	F	22	12
	T	6	24



A2 vs A0+A1+A3	
accuracy	75.00%
Fisher's exact test	p-value: 2.26E-04
odds ratio	9.50


		result	
		F	T
prediction	F	34	4
	T	12	14



A3 vs A0+A1+A2	
accuracy	82.81%
Fisher's exact test	p-value: 2.30E-03
odds ratio	11.08


		result	
		F	T
prediction	F	47	3
	T	8	6

B




F0 vs F1+F2+F3	
accuracy	87.50%
Fisher's exact test	p-value: 4.95E-02
odds ratio	14.25

		result	
		F	T
prediction	F	54	1
	T	7	2




F1 vs F0+F2+F3	
accuracy	64.62%
Fisher's exact test	p-value: 2.73E-02
odds ratio	3.16

		result	
		F	T
prediction	F	21	13
	T	10	20



F2 vs F0+F1+F3	
accuracy	70.31%
Fisher's exact test	p-value: 3.24E-03
odds ratio	6.39


		result	
		F	T
prediction	F	33	4
	T	15	12



F3 vs F0+F1+F2	
accuracy	73.44%
Fisher's exact test	p-value: 1.35E-02
odds ratio	5.80

		result	
		F	T
prediction	F	39	4
	T	13	8

**Figure 7. Determining liver inflammation grade and fibrotic stage using miRNA expression pattern in LOOCV analysis.** A. In order to diagnose the grade of liver inflammation, A0 was identified first. Next A1, A2, and A3 were identified in a similar manner as A0. For each, the accuracy rate, P value, and the odds ratio are shown. B. For liver fibrosis stage, F0 was first diagnosed following which the other stages F1, F2, and F3 were diagnosed in a similar manner. For each group the accuracy rate, P value, and the odds ratio are shown.  
doi:10.1371/journal.pone.0048366.g007



**Figure 8. Real-time qPCR validation of microarray analysis.** The microarray expression analysis result of four miRNAs was reproduced in real-time PCR analysis. The pairs with  $p < 0.001$  are marked by “\*\*\*”.  
doi:10.1371/journal.pone.0048366.g008

All reactions were run in triplicate. Chromo 4 detector (Bio-rad) was used to detect miRNA expression. To allow for the validation of microarray results with  $C(t)$  obtained by qPCR, raw gene expressions were transformed into logarithmic values. P-values were computed via one-sided t test. No averages over probes were taken for the microarray. The above procedures were also done with various packages/functions implemented in R (<http://www.r-project.org/>).

#### Statistical Analysis

For symptoms having discrete values, grade pairs were compared with Wilcoxon rank sum test (one-sided); otherwise, P-values were computed from correlation coefficients. In both cases, false discovery rate (FDR) of less than 0.05 computed from the P-value was regarded as significant. Benjamini and Hochberg criterion was used for FDR estimation. All p-values shown are significant even though they are raw numbers. No average over probes was taken before correlation analyses.

#### The Canonical Correlation Coefficients for miRNA Expression and Clinical Parameters

The canonical correlation coefficients were computed for ALT-miRNA, albumin-miRNA, and HCVRNA-miRNA correlations, using up to 12 miRNA with larger correlation coefficients (see Supporting Information).

#### Classification Analyses for Liver Fibrosis/inflammation

P-values were computed via one-sided t test using the raw expression values of each miRNA from the samples of CHC

and healthy controls. The logarithm of obtained P-values was then transformed into principal components scores via principal components analysis. Following this, grades were discriminated by linear discriminant analysis of CHC ages and the optimal number of principal components.


#### Selection of miRNAs Required to Diagnose Several Liver Diseases

For specific pairs consisting of one liver disease and a healthy control, their normalized miRNAs expression was transformed into principal components scores via principal components analysis. miRNAs having the larger first and second principal component scores were selected. Following this, the principal component scores of each sample was computed based solely on the selected miRNA expressions. Liver diseases were classified using the optimal number of these principal component scores.

In order to compensate for the relative small number of NASH and CHB patients, we performed “*in silico*” patients resampling analysis of the microarray data (see Supporting Information). All the above procedures were done with various packages/functions implemented in R.

#### “*In silico*” Resampling

“*In silico*” resampling is a tool often used to overcome the limitation of a small sample size. Using this technique, we combined the clinical traits of existing patients and created various virtual samples. Using these virtual cohorts, we were then able to increase the sample size (see Supporting information).



**Figure 9. The list of miRNAs used to obtain the maximum correlation coefficient between miRNA expression level, and clinical characteristics.** Pairwise heatmap showing miRNAs and their correlation coefficient and p-values. doi:10.1371/journal.pone.0048366.g009

In order to validate the “*in silico*” resampling results, we prepared another sample set and once again performed “*in silico*” resampling using the microarray data from 99 CHC liver tissue samples [36]. The results proved that “*in silico*” resampling can accurately reproduce an entire population using only a small number of existing samples (see Supporting Information).

### Reproducibility Test of Microarray Data

Data were analyzed using the GeneSpring GX10.0.2 (Agilent). Quality control (QC) was applied according to the manufacturer’s instructions, and all data were approved by GeneSpring. Following Agilent recommendations, no inter-array normalization was applied because the similarity in miRNA expression among sample arrays was unknown [37]. Scatter plots and Pearson’s pairwise correlations were performed with GeneSpring.

### Supporting Information

**Figure S1** Expression patterns of miRNAs used for discriminating among CHC, NL, CHB, and NASH. Classifying CHC, NL, CHB, and NASH using LOOCV. Distinguishing between two arbitrary groups using LOOCV. (TIF)

**Figure S2** Expression patterns of miRNAs used to discriminate among CHC, CHB, NASH, and NL “*in silico*” resampling for disease discriminant studies reflected by BMI. A. Box plots of expression pattern of the miRNAs used to discriminate among CHC, CHB, NASH, and NL. B. Discriminating among four groups using LOOCV. Accuracy is 95.25%. C. Two dimensional embedding of CHC, CHB, NASH, and NL by the first and second principle component scores computed with 12 selected miRNAs (TIF)

**Figure S3** The same as Fig.3 for CHC and CHB. A. Box plot of 19 miRNAs used for the discrimination. B. Classification between CHC and CHB. Accuracy is 100%. C. The two dimensional embedding of CHB and CHC by the first and second principal component scores computed with 19 selected miRNAs. (TIF)

**Figure S4** The same as Fig.S3 for CHC and NASH. A. Box plots of 20 miRNAs used for the discrimination. B. Classification between CHC and NASH. Accuracy is 100%. C. Two dimensional embedding of CHC and NASH by the first and second principal component scores computed with 19 selected miRNAs (TIF)

**Figure S5** The same as Fig.S3 for CHC and NL. A. Box plots of 9 miRNAs used for the discrimination. B. Classification between CHC and NL. Accuracy is 100%. C. Two dimensional embedding of CHC and NL by the first and second principal component scores computed with 9 selected miRNAs (TIF)

**Figure S6** The same as Fig.S3 for CHB and NL. A. Box plots of 4 miRNAs used for the discrimination. B. Classification between CHB and NL. Accuracy is 93.5%. C. Two dimensional embedding of CHB and NL by the first and second principal component scores computed with 4 selected miRNAs (TIF)

**Figure S7** The same as Fig.S3 for NASH and NL. A. Box plots of 5 miRNAs used for the discrimination. B. Distinguishing between NASH and NL with 84.0% accuracy. C. Two

dimensional embedding of NASH and NL by the first and second principal component scores computed with 5 selected miRNAs (TIF)

**Figure S8** The same as Fig.S3 for CHB and NASH pair. A. Box plots of 17 miRNAs used for the discrimination. B. Distinguishing between CHB and NASH with 80.0% accuracy. C. Two dimensional embedding of CHB and NASH by the first and second principal component scores computed with 17 selected miRNAs (TIF)

**Figure S9** Classification of the independent sample using semi-supervised learning based on the labels in the original cohort. A. Classifying CHB and CHC. Accuracy is 74.47%. B. Classifying CHC and NASH. Accuracy is 87.18%. C. Classifying CHB and NASH. Accuracy is 79.19%. (TIF)

**Figure S10** miRNA expression pattern that correlated with the changes in clinical background. miRNAs that were differentially expressed according to the grade of liver inflammation (TIF)

**Figure S11** miRNA expression pattern that correlated with the changes in clinical background. miRNAs that were differentially expressed according to liver fibrosis stage (TIF)

**Figure S12** Real-time qPCR validation of microarray analysis “*in silico*” resampling for disease discrimination studies reflected by BMI. The result of microarray expression analysis of four miRNAs was reproduced using real-time PCR analysis. Pairs with  $p < 0.001$  are marked by “\*\*\*\*”. (TIF)

**Figure S13** The relationship between the expression levels of several miRNAs and serum ALT, albumin, HCVRNA, respectively. Horizontal axis shows the number of miRNAs used in the analysis. Vertical axis shows the correlation index and p-values. (TIF)

**Figure S14** Summary of the relationship between the expression level of miR-122 and several clinical features. A. Expression level of miR-122 positively correlated with an increase in liver inflammatory grade. Asterisk denotes significant differences of  $p < 0.05$ . B. Expression level of miR-122 positively correlated with the serum level of albumin. C. Expression level of miR-122 positively correlated with the amount of serum HCVRNA. D. Expression level of miR-122 in exosome rich fraction did not significantly correlate with that in liver tissues. (TIF)

**Table S1** The list of miRNAs used for classifying arbitrary 2 groups and 4 groups, and their p-values. (DOCX)

**Table S2** Significantly differentially expressed miRNAs according liver inflammation grade and liver fibrotic stage. (DOCX)

**Table S3** The list of miRNAs used to obtain the maximum correlation coefficient between expression level of miRNAs, and clinical characteristics. (DOCX)

**Table S4** List of miRNAs with expression that corresponded in liver tissue and serum. (DOCX)

**Table S5** Clinical background of original samples and independent samples in detail.

(DOCX)

**Table S6** Accuracy of LDA for “in silico” resampling.

(DOCX)

## References

- Ambros V (2004) The functions of animal microRNAs. *Nature* 431: 350–355.
- Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, et al. (2011) The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. *PLoS One* 6: e16081.
- Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. *Oncogene* 25: 2537–2545.
- Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. *Semin Oncol* 38: 752–763.
- Hsu SH, Wang B, Kota J, Yu J, Costinean S, et al. (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. *J Clin Invest* 122: 2871–2883.
- Tsai WC, Hsu SD, Hsu GS, Lai YC, Chen SJ, et al. (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. *J Clin Invest* 122: 2884–2897.
- Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 9: 654–659.
- Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J Biol Chem* 285: 17442–17452.
- Zhang Y, Liu D, Chen X, Li J, Li L, et al. (2010) Secreted monocytic miR-150 enhances targeted endothelial cell migration. *Mol Cell* 39: 133–144.
- Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes. *Proc Natl Acad Sci U S A* 107: 6328–6333.
- Kogure T, Lin WL, Yan IK, Braconi C, Patel T (2011) Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. *Hepatology* 54: 1237–1248.
- Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 9: 581–593.
- Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, et al. (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat Commun* 2: 282.
- Meckes DG Jr, Shair KH, Marquitz AR, Kung GP, Edwards RH, et al. (2010) Human tumor virus utilizes exosomes for intercellular communication. *Proc Natl Acad Sci U S A* 107: 20370–20375.
- Gould SJ, Booth AM, Hildreth JE (2003) The Trojan exosome hypothesis. *Proc Natl Acad Sci U S A* 100: 10592–10597.
- Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Sci* 101: 2087–2092.
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A* 105: 10513–10518.
- Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 18: 997–1006.
- Lawrie CH (2007) MicroRNAs and haematology: small molecules, big function. *Br J Haematol* 137: 503–512.
- Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. *PLoS One* 6: e23937.
- Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Hauptenthal J, et al. (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 106: 1663–1669.
- Ji F, Yang B, Peng X, Ding H, You H, et al. (2011) Circulating microRNAs in hepatitis B virus-infected patients. *J Viral Hepat* 18: e242–251.
- Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, et al. (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. *Hepatology* 54: 1767–1776.
- Chapelle O, Scholkopf B, Zien A (2006) Semi-supervised learning. Cambridge, Mass.: MIT Press. x, 508 p. p.
- Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. *PLoS One* 3: e3694.
- Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, et al. (2010) Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. *Lab Invest* 90: 1727–1736.
- Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. *J Proteomics* 73: 1907–1920.
- Simons M, Raposo G (2009) Exosomes—vesicular carriers for intercellular communication. *Curr Opin Cell Biol* 21: 575–581.
- Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, et al. (2011) Toward the blood-borne miRNome of human diseases. *Nat Methods* 8: 841–843.
- Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al. (2009) Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. *Clin Chem* 55: 1977–1983.
- Nathwani RA, Pais S, Reynolds TB, Kaplowitz N (2005) Serum alanine aminotransferase in skeletal muscle diseases. *Hepatology* 41: 380–382.
- Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell* 129: 1401–1414.
- Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 33: 525–540.
- Bedossa P, Poinard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 24: 289–293.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 116: 1413–1419.
- Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, et al. (2010) Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. *BMC Med Genomics* 3: 48.
- Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, et al. (2008) An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. *J Mol Diagn* 10: 513–519.

## Author Contributions

Conceived and designed the experiments: YM NK TO YT. Performed the experiments: YM HT TT YY NK. Analyzed the data: TT YT. Contributed reagents/materials/analysis tools: HT JT TK. Wrote the paper: YM NK TO.

**Original Article**

## Follow up of the 987 blood donors found with hepatitis C virus infection over 9–18 years

Junko Matsuo,<sup>1</sup> Masaaki Mizui,<sup>3</sup> Hajime Okita,<sup>3</sup> Keiko Katayama,<sup>1</sup> Shiomi Aimitsu,<sup>4</sup> Tatsuro Sakata,<sup>5</sup> Makoto Obayashi,<sup>6</sup> Toshio Nakanishi,<sup>7</sup> Kazuaki Chayama,<sup>2</sup> Yuzo Miyakawa,<sup>9</sup> Hiroshi Yoshizawa<sup>8</sup> and Junko Tanaka<sup>1</sup> for the Hiroshima Hepatitis Study Group

<sup>1</sup>Department of Epidemiology, Infectious Disease Control and Prevention, <sup>2</sup>Department of Medicine and Molecular Sciences, Graduate School of Biomedical Sciences, Hiroshima University, <sup>3</sup>Hiroshima Red Cross Blood Center, <sup>4</sup>Hiroshima Red Cross Hospital, <sup>5</sup>National Hospital Organization Fukuyama Medical Center, <sup>6</sup>Onomichi General Hospital, <sup>7</sup>Miyoshi Chuo Hospital, Hiroshima, <sup>8</sup>Hiroshima University, Hiroshima, and <sup>9</sup>Miyakawa Memorial Research Foundation, Tokyo, Japan

**Aim:** To follow up blood donors found with hepatitis C virus (HCV) infection, to improve the outcome by antiviral treatments.

**Methods:** Between 1991 and 2001, 3377 of the 1 925 860 donors (0.18%) were found to have HCV infection at the Hiroshima Red Cross Blood Center in Japan. Of them, 987 were able to be followed regularly over 9–18 years until 2009, and received antiviral treatments as required.

**Results:** At the start, chronic hepatitis was diagnosed in 541 (54.8%), cirrhosis in five (0.5%) and hepatocellular carcinoma (HCC) in one (0.1%), whereas the remaining 439 (44.5%) had persistently normal aminotransferase levels (PNAL). Hospital visits were terminated voluntarily in 24.3% within the first year, 46.8% by 10 years and 50.9% by 17 years. Liver disease improved in 178 (18.0%), remained stable in 606 (61.4%) and aggravated in 170 (17.2%). Of the 541 donors with chronic

hepatitis, HCC developed in 28 (5.2%) and cirrhosis in 11 (2.0%), whereas HCV infection was cleared in 107 (19.8%) by antiviral treatments. In addition, HCV infection resolved in 54 of the 439 donors (12.3%) with PNAL after they had developed chronic hepatitis and received treatments. In donors with chronic hepatitis, the cumulative incidence of HCC was 4.1% at 10 years. By multivariate analysis, age and diagnosis of chronic hepatitis at the entry were found to be independent risk factors for the development of HCC.

**Conclusion:** Individuals with undiagnosed HCV infection need to be identified and receive medical care. They have to be motivated to merit from this health-care program.

**Key words:** alanine aminotransferase, chronic hepatitis C, hepatitis C virus, hepatocellular carcinoma, interferon, natural history

**INTRODUCTION**

OVER THE WORLD, an estimated 130–170 million people are infected with hepatitis C virus (HCV),<sup>1</sup> and most of them are unaware of their HCV infection. Because HCV infection evolves insidiously, it takes decades before overt liver disease develops, such as decompensated cirrhosis and hepatocellular carcinoma

(HCC).<sup>2</sup> Hence, it is necessary to identify individuals with undiagnosed HCV infection, and provide them with medical care for clearing HCV and preventing severe liver disease developing in them.

To make plans for management of individuals with undiagnosed HCV infection, it needs to be established to what extent liver disease has progressed in them, and how it advances over the long run, with or without medical interventions. Blood donation offers a unique opportunity to pursue such an undertaking, because it can identify HCV infections that have not been diagnosed previously.<sup>3–9</sup>

In 1991, when screening for antibody to HCV (anti-HCV) was introduced, a program was launched by the Hiroshima Hepatitis Study Group in Japan to identify HCV carriers at the blood donation. Liver disease was

Correspondence: Dr Junko Tanaka, Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Email: jun-tanaka@hiroshima-u.ac.jp  
Received 7 November 2011; revision 16 December 2011; accepted 4 January 2012.

diagnosed in the donors infected with HCV, so as to provide them with medical care to prevent the development of serious complications. Initially, 1019 blood donors with HCV infection were enrolled in the program, and the outcome was reported for 408 (40.0%) of them who had been followed for 5 years or longer by the year 2003.<sup>10</sup>

Here, we report the outcome of liver disease in 987 (96.9%) of them over 18 years of follow up. Various issues came up during the study, and they would need to be taken into consideration for improving health-care of the population with undiagnosed HCV infection hidden in the society. Further, the obtained results are hoped to lessen the national burden for management of hepatitis C that is expected to increase substantially in the foreseeable future.

## METHODS

### Study population

**B**ETWEEN AUGUST 1991 and November 2001, 1 925 860 individuals wished to donate blood at the Japanese Red Cross (JRC) Hiroshima Blood Center, and 3377 (0.18%) were found to have HCV infection with high-titered anti-HCV and HCV RNA in the serum. They were informed of their HCV infection, and recommended to consult hepatology specialists in the 20 institutions constituting the Hiroshima Hepatitis Study Group: Hiroshima City Asa Hospital, Akitsu Prefectural Hospital, Hiroshima Prefectural Hospital, Kure City Medical Association Hospital, Kure Kyosai Hospital, Hiroshima University Hospital, KKR Hiroshima Kinen Hospital, Hiroshima City Hospital, Hiroshima Red Cross Hospital, Hiroshima General Hospital, Hiroshima JR Hospital, National Hospital Organization Kure Medical Center, National Hospital Organization Fukuyama Medical Center, Mitsubishi Mihara Hospital, Shobara Red Cross Hospital, Chugoku Rousai Hospital, Chuden Hospital, Nippon Kokan Fukuyama Hospital, Onomichi General Hospital and National Hospital Organization West Medical Center. Serving there as hepatology specialists were: Keiji Tsuji, M.D., Toshio Miura, M.D., Mikiya Kitamoto, M.D., Norihiko Katayama, M.D., Shuji Yamaguchi, M.D., Shoichi Tanakahshi, M.D., Hideaki Kodama, M.D., Yasuyuki Araki, M.D., Yasuyuki Aisaka, M.D., Kunio Ishida, M.D., Keitaro Yamashina, M.D., Hiroshi Kouno, M.D., Toshihiko Kaneyoshi, M.D., Kazushi Teramen, M.D., Kouji Kamada, M.D., Takashi Moriya, M.D., Hiroto Ishihara, M.D., Tomoo Yoshida, M.D., and Makoto Obayashi, M.D.

Of the 3377 donors infected with HCV, who were advised to undergo medical examination, 1097 (32.5%) visited liver clinics. The initial diagnosis was established in 1019 of them (30.2% of the total), and the date of initial visit, the date of birth and the baseline liver disease were filed in the computer. They were recommended to take regular check-ups, and receive antiviral treatment as required. The results of 408 carriers (40.0%), who had been followed for 5 years or longer, were reported in 2007.<sup>10</sup> Since then, they had been followed for an additional 6 years. The present study compiled all the data that had been accumulated on them over 18 years from 1991 to 2009, in an attempt to portray the outcome of undiagnosed HCV infection, and evaluate the efficacy of preventing liver disease by antiviral treatments. The 32 donors with normal aminotransferase levels at the initial diagnosis were excluded, because they visited clinics only once, and therefore the diagnosis of liver disease was not established in them. The remaining 987 donors entered the present study.

The study design conformed to the Declaration of Helsinki, and was approved by the Ethic Committees of Hiroshima University. Informed consent was obtained from each blood donor who was infected with HCV.

### Data collection

A questionnaire form was distributed among hepatology specialists in the 20 institutions of the Hiroshima Hepatitis Study Group. They were asked to log the following: (i) initial diagnosis; (ii) compliance to regular visits; (iii) changes in liver disease over time; (iv) treatments with interferon (IFN); and (v) development of HCC. These data were made anonymous for the personal identification of any participant, and analyzed collectively.

### Diagnosis of liver disease

Four clinical states were classified. They were: (i) persistently normal aminotransferase levels (PNAL); (ii) chronic hepatitis; (iii) cirrhosis; and (iv) HCC. PNAL was judged by: (i) values of alanine aminotransferase (ALT) within normal limits ( $\leq 40$  IU/L) twice or more within 6 months at least 2 months apart; (ii) normal platelet counts ( $\geq 150 \times 10^3/\text{mm}^3$ ); (iii) lack of abnormal findings in those examined by imaging modalities; and (iv) no pathological findings in the liver biopsy for those who received it. Each attending specialist was asked his/her comprehensive opinion on the absence of liver disease in the HCV-infected donor with PNAL. The

diagnosis of chronic hepatitis, cirrhosis and HCC was left to the judgment of the attending hepatology specialist, who took into consideration the results of biochemical, imaging and other tests. The specialist made the decision as to whether his/her patient should receive IFN-based treatment or would better be followed regularly without treatment.

### Markers of HCV infection

Hepatitis C virus RNA was determined by reverse-transcription polymerase chain reaction (RT-PCR) with primers deduced from conserved sequences in the 5'-non-coding region of the genome, irrespective of genotypes.<sup>11</sup> Genotypes of HCV were determined by RT-PCR with type-specific primers<sup>12</sup>

### Genotypes of the interleukin 28B (IL28B) gene

The three donors who cleared HCV spontaneously were examined for *IL28B* genotypes.<sup>13–15</sup> The genomic DNA was extracted from the serum by RT-PCR, and polymorphisms of the *IL28B* gene at rs12979860 and rs8099917 were determined by the direct sequencing.

### IFN-based treatments

Interferon was administrated according to the regular protocol at the discretion of the attending doctor and with the agreement of his/her patient. Types of IFN were natural IFN- $\alpha$ , recombinant IFN- $\alpha$ 2 and - $\alpha$ 2b until 2002. Natural IFN or recombinant IFN- $\alpha$ 2a or - $\alpha$ 2b at a daily dose of 6–9 million units (MU) was administrated during the initial 2 weeks, followed by 3 MU three times per week until 24 weeks after the start of IFN (total dose, 300–342 MU). After 2002, ribavirin was combined with recombinant IFN. After 2005, the standard-of-care therapy was implemented with pegylated-IFN- $\alpha$ 2b (PEG-Intron; Shering Plough, Kenilworth, NJ) s.c. at a median dose of 1.5  $\mu$ g/kg [range, 1.3–2.0  $\mu$ g/kg] once a week until 48 weeks, together with a daily dose of 600–1000 mg ribavirin (Rebetol [600–1000 mg]; Shering Plough) that was adjusted by the bodyweight. Sustained virological response (SVR) to IFN was diagnosed by the clearance of HCV RNA from serum 24 weeks after the treatment completion and thereafter.

### Statistical analyses

Means and proportions were compared between groups by Student's *t*-test and  $\chi^2$ -test or Fisher's

exact test, respectively. For comparison of the frequency of the response to IFN (SVR and non-SVR) and the lack of IFN treatments in blood donors in whom liver disease was improved, unchanged and aggravated, post-hoc pairwise comparisons were carried out using the  $\chi^2$ -test, and the *P*-value was adjusted by the method of Bonferroni. The Kaplan–Meier's life-table analysis and Cox proportional hazards models were employed in assessing the risk of developing chronic hepatitis or HCC with reference to sex, age and diagnosis at the entry, as well as the response to IFN-based treatments, utilizing JMP ver. 9 software (SAS Institute, Cary, NC, USA). All *P*-values were two-tailed, and those less than 0.05 were considered statistically significant.

## RESULTS


### Compliance with the follow up of blood donors who had HCV infection

FIGURE 1 ILLUSTRATES the compliance with follow up and shifting status of blood donors with HCV over 18 years. Notably, 24.3% of them were lost to follow up within the first year. Dropouts increased to 46.8% at 10 years and reached 51.6% at 15 years. Exclusive of the 52 blood donors, who entered the study in the first year and were followed for 18 years, only approximately 20% of donors with HCV infection complied with observation between 14 and 17 years. HCV was cleared in 17.4% of them over 17 years, including 8.3% who complied with observation and 9.1% who were lost to follow up.

### Liver disease in the 987 blood donors with HCV infection

Clinical states of the 987 blood donors with HCV infection, at the time of donation, are summarized in Table 1. Cirrhosis had developed in five (0.5%) and HCC in one (0.1%) already. Chronic hepatitis was diagnosed in 541 (54.8%) of them, leaving only 439 donors (44.5%) who had PNAL. Acute hepatitis was diagnosed in a single donor infected with HCV-2a, who had been negative for HCV RNA at the previous donation. He developed chronic hepatitis 9 months later, and achieved SVR to antiviral treatment 1 year thereafter. Chronic hepatitis was more frequent in men than women (65.7% vs 45.2%, *P* < 0.001). Conversely, women possessed PNAL more often than men (54.4% vs 33.3%, *P* < 0.001). Liver biopsy was performed in





**Figure 1** Follow up of the 987 donors with hepatitis C virus (HCV) infection over 18 years. □, on observation (HCV kept); □, on observation (HCV cleared); □, lost to follow up (HCV cleared); □, transferred (HCV kept); □, deceased (HCV kept); □, lost to follow up (HCV kept).

356 (36.1%) of the 987 donors, and 393 (39.8%) received IFN-based treatments. Among the 709 donors, for whom genotyping was feasible, genotype 1b was the most prevalent both in men (67.6%) and women (65.7%).

### Evolution of liver disease in the 987 donors with HCV during the follow up

Figure 2 depicts the outcome of 987 blood donors with HCV infection during an average follow-up period

**Table 1** Clinical states of the 987 blood donors found with HCV infection at the donation

Features	Total (n = 987)	Men (n = 463)	Women (n = 524)	Differences Men vs. Women
Persistently normal aminotransferase levels	439 (44.5%)	154 (33.3%)	285 (54.4%)	$P < 0.001$
Chronic hepatitis	541 (54.8%)	304 (65.7%)	237 (45.2%)	$P < 0.001$
Cirrhosis	5 (0.5%)	3 (0.7%)	2 (0.4%)	$P = 0.670$
Hepatocellular carcinoma	1 (0.1%)	1 (0.2%)	0	$P = 0.470$
Acute hepatitis	1 (0.1%)	1 (0.2%)	0	$P = 0.470$
Age at the entry	45.1 ± 11.3	43.2 ± 11.1	46.8 ± 11.2	$P < 0.001$
Observation period (years)	7.3 ± 6.6	6.8 ± 6.4	7.7 ± 6.8	$P = 0.024$
Biopsy	356 (36.1%)	181 (39.1%)	177 (33.8%)	$P = 0.096$
IFN-based therapy	393 (39.8%)	190 (41.0%)	203 (38.7%)	$P = 0.503$
SVR	166 (42.2%)	84 (44.2%)	82 (40.4%)	$P = 0.507$
Genotypes identified	709 (71.8%)	339 (73.2%)	370 (70.6%)	$P = 0.402$
Genotype 1b	472 (66.6%)	229 (67.6%)	243 (65.7%)	$P = 0.366$
Genotype 2a	153 (21.6%)	71 (20.9%)	82 (22.2%)	$P = 0.962$
Genotype 2b	68 (9.6%)	35 (10.3%)	33 (8.9%)	$P = 0.512$
Mixed Genotype	16 (2.3%)	4 (1.2%)	12 (3.2%)	$P = 0.129$

SVR, sustained virological response.




Figure 2 Outcome of hepatitis C virus (HCV) donors with HCV infection. ○, improved (n = 178); ◐, unchanged (n = 606); ●, aggravated (n = 170). PNAL, persistently normal aminotransferase levels.

of 7.3 ± 6.6 years; they were stratified by the initial diagnosis. Liver disease improved in 178 (18.0%), and remained stable in 606 (61.4%), whereas it worsened in the remaining 170 (17.2%). HCV infection was cleared by antiviral treatments in 107 of the 541 donors (19.8%) with chronic hepatitis. Chronic hepatitis developed in 120 of the 439 donors (27.3%) with PNAL. Of them, HCV infection was cleared in 54 by treatments given after they had developed chronic hepatitis, whereas it resolved spontaneously in two. Cirrhosis occurred in 16 donors (1.6%), including 11 with chronic hepatitis and five with PNAL at entry. HCC developed in 34 donors (3.4%), and in three of them, it was detected at 1, 4 and 7 years, respectively, after they had cleared HCV infection by antiviral treatments.

**Cumulative incidence of chronic hepatitis in donors with PNAL**

Figure 3 shows the cumulative incidence of chronic hepatitis in the 439 donors with PNAL. Chronic hepatitis developed in 36.2% by 5 years, 51.5% by 10 years and 72.9% by 15 years, with an annual incidence of 4.9-7.2% (Fig. 3a). Men tended to develop chronic hepatitis more frequently than women (Fig. 3b).

Figure 3c compares the development of chronic hepatitis in donors with PNAL classified into four age groups. Chronic hepatitis developed in the group aged 40-49 years at entry, more frequently than in those aged 39 years or younger or 50 years or older, although the difference fell short of being significant (P = 0.089). The cumulative incidence of chronic hepatitis reached 66.3% by 10 years in the group aged 40-49 years at entry.

**Development of HCC in donors with chronic hepatitis**

Overall, 680 donors (68.9%) were diagnosed with chronic hepatitis either at entry or during this study, and they were followed for the development HCC. The cumulative incidence of HCC was 9.0% by 15 years after they had been diagnosed with chronic hepatitis (Fig. 4a). HCC developed comparably frequently in men and women (Fig. 4b). It developed more frequently (P < 0.001) in the donors in whom chronic hepatitis had been diagnosed at ages 60 years or older than 59 years or younger (Fig. 4c). HCC occurred less frequently (P = 0.037) in responders than non-responders to IFN, or the donors who did not receive IFN (Fig. 4d).




Figure 3 Cumulative incidence of chronic hepatitis in the 439 donors with persistently normal aminotransferase levels (PNAL). Development of chronic hepatitis is depicted in the total donors with PNAL (a), those stratified by sex (b), and those in different age groups (c). (b)  $\leq 39$ , (n = 154); Women, (n = 285); (c)  $\leq 39$ , (n = 131); 40-49, (n = 123); 50-59, (n = 145);  $\geq 60$ , (n = 40).

Independent risk factors for the development of HCC were sorted by multivariate analysis (Table 2). Age at the diagnosis of chronic hepatitis was the highest risk (Odds Ratio [OR], 22.70 for  $\geq 60$  years), followed by the initial diagnosis of chronic hepatitis (OR, 6.52) and the male sex (OR, 1.78). Failure to gain SVR to IFN (OR, 2.11), or the lack of IFN-based treatment (OR, 2.06), increased the risk of HCC, as well.

**Influence of the response to IFN on the outcome of donors**

Of the 476 donors with PNAL or chronic hepatitis, who had been followed for 5 years or longer, 280 (58.8%) received IFN-based treatments, and the outcome of liver disease was evaluated with reference to the response in three combinations, namely, SVR versus non-SVR, SVR versus without IFN, and non-SVR versus without IFN (Table 3). Of the 50 patients with improvement in liver disease, SVR was more frequent than non-SVR and without IFN ( $P < 0.001$  for both). Of the 281 patients in whom liver disease did not change, SVR was more frequent than without IFN ( $P < 0.001$ ), and non-SVR was more frequent than without IFN ( $P < 0.01$ ). There were no differences among the frequency of SVR, non-SVR and without IFN in the 145 patients in whom liver disease aggravated.

**Spontaneous clearance of HCV infection**

Hepatitis C virus RNA was cleared from the serum in three donors who had not received antiviral treatments (Table 4). HCV RNA disappeared 6, 15 and 15 years, respectively, after they had been found with HCV infection at the blood donation. Two of them had PNAL and the remaining one had chronic hepatitis at entry. HCV genotypes were able to be determined in two, and they were 2a and 2b, respectively; neither of them was infected with the genotype 1b that is most prevalent and detected in 82% of Japanese blood donors.<sup>12</sup> All three donors possessed CC at rs12979860 and TT at rs8099917 in the *IL28B* gene, which increase the response to IFN in hepatitis C patients,<sup>13-15</sup> and promote the spontaneous clearance of HCV infection.<sup>16</sup> Among




Figure 4 Cumulative incidence of hepatocellular carcinoma (HCC) in donors with chronic hepatitis. Development of HCC is portrayed in the 680 donors since the day of diagnosis with chronic hepatitis (start point) till the day of diagnosis with HCC (end-point) (a). Influence of sex (b), age (c) and interferon (IFN)-based treatments (d) is evaluated, also. (b) Men, (n = 345); Women, (n = 335); (c) ≥ 60, (n = 81); 50-59, (n = 225); 40-49, (n = 186); ≤ 39, (n = 188); (d) Non-SVR, (n = 175); Without IFN, (n = 345) SVR, (n = 160). SVR, sustained virological response.

the 316 donors with PNAL who did not receive IFN treatment, HCV was cleared spontaneously in only two, at the rate of 13.0/10<sup>4</sup> person-years (95% confidence interval, 1.6-47.1/10<sup>4</sup> person-years).

### DISCUSSION

A LONG-TERM prospective study was performed on blood donors who were found to have HCV infection. For 18 years (1991-2009), 987 donors with HCV infection were followed up for an average of 7.3 years. The entry to this study was started in 1991 when an anti-HCV test was introduced to blood screening, and terminated in 2000 when merely a few donors were found to have HCV infection at the Hiroshima Red Cross Blood Center annually.<sup>17</sup> Despite our initial expectation, only one-third (32.5%) of blood donors with HCV infection visited liver clinics, even though they were advised to do so strongly. Another distressing issue was the low compliance with the study (Fig. 1). Within the first year after the entry, 24.3% of donors ceased to visit liver clinics. The rate of dropouts increased gradually to 46.8% over 10 years; it plateaued thereafter and stayed at 50.9% over 17 years. Thus, approximately one-half of blood donors with HCV infection were unable to receive any possible benefit of this study. It is not known whether these dropouts differed from the followed donors in the outcome of HCV infection and response to IFN-based treatments. Therefore, there remain possible biases in the results obtained only in the followed donors in the present study. We can say that the symptoms at the onset were almost the same among donors because they were well enough to give someone their blood regardless of whether they consulted later or not. It is of utmost importance to motivate blood donors with HCV infection to visit liver clinics, and encourage early dropouts to stay in follow up, to gain the full effect of screening blood donors.

Over 17 years of follow up, IFN-based treatments cleared HCV infection in 17.4%. Restricted to the